# Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension

> **NCT00503360** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 80 (estimated)

## Conditions studied

- Ocular Hypertension

## Interventions

- **DRUG:** SAD448

## Key facts

- **NCT ID:** NCT00503360
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2008-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503360, "Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00503360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*